$3.71 Billion is the total value of BVF INC/IL's 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 30.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $142,548,533 | +6.7% | 5,283,489 | -7.0% | 3.84% | +3.3% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $110,199,948 | -34.1% | 3,981,212 | -36.4% | 2.97% | -36.3% |
| GLPG | Sell | GALAPAGOS NVspon adr | $66,167,016 | -24.8% | 1,915,109 | -11.5% | 1.78% | -27.3% |
| CNTA | Sell | CENTESSA PHARMACEUTICALS PLCsponsored ads | $58,896,759 | +1.0% | 9,103,054 | -3.4% | 1.59% | -2.3% |
| RLAY | Sell | RELAY THERAPEUTICS INC | $19,896,420 | -49.2% | 2,365,805 | -24.2% | 0.54% | -50.8% |
| ALLK | Sell | ALLAKOS INC | $19,413,987 | -48.5% | 8,552,417 | -1.2% | 0.52% | -50.1% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $13,791,262 | -42.5% | 1,259,476 | -30.4% | 0.37% | -44.3% |
| DCTH | Sell | DELCATH SYS INC | $3,953,403 | -42.5% | 976,149 | -17.2% | 0.11% | -44.3% |
| Sell | BIONOMICS LIMITEDads | $127,904 | -28.2% | 47,372 | -41.5% | 0.00% | -40.0% | |
| Exit | GALMED PHARMACEUTICALS LTD | $0 | – | -89,853 | -100.0% | -0.01% | – | |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -6,353,645 | -100.0% | -0.04% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -4,996,565 | -100.0% | -0.07% | – |
| ARAV | Exit | ARAVIVE INC | $0 | – | -4,784,214 | -100.0% | -0.17% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.